Highest-materiality recent filing
AptarGroup names Aditya Gandhi CAO; effective June 8, replaces Ackerman
Aditya Gandhi appointed Vice President, CAO; effective June 8, 2026.
Directors Fotiades, Matthews, Owens, and Xing reelected; support ranged from 49.6M to 54.1M votes.
Aptar Q1 adjusted EPS $1.19 (-8% YoY); names Gael Touya CEO effective Sept 1
Reported sales up 11% to $982.9M; core sales flat; net income down 8% to $73M.
AptarGroup CEO Stephan Tanda to retire Sept 1, 2026; Gael Touya appointed successor
CEO Tanda to retire effective Sep 1, 2026; will serve as strategic advisor through Dec 31, 2026 and remain on Board until year-end.
Aptar Q4 net income down 26%, adjusted EPS $1.25 vs $1.62; new $600M buyback
Reported sales +14% to $963M (core +5%); net income -26% to $74M ($1.13 EPS).
AptarGroup closes $600M offering of 4.750% Senior Notes due 2031
$600M principal; 4.750% coupon, semi-annual; matures March 30, 2031.
Reported sales $961M (+6% YoY); core sales +1%. Reported EPS $1.92 (+30%); adjusted EPS $1.62 (+4%).
AptarGroup Q2 2025: adj. EPS $1.66 (+18% YoY), sales $966M (+6%), adj. EBITDA margin 22.6%
Reported sales $966M (+6% YoY); core sales +3%; net income $112M (+24%); adj. EPS $1.66 vs $1.41.
AptarGroup shareholders approve 1M share increase for 2018 equity plan
Amendment to 2018 Equity Plan adding 1,000,000 shares approved; 55,973,606 for, 1,397,174 against.
AptarGroup Q1 2025: sales down 3% to $887M, adjusted EPS $1.20, guides Q2 EPS $1.56-$1.64
Reported sales down 3% to $887M; net income down 5% to $79M; adjusted EPS $1.20 vs $1.22 prior year.
AptarGroup Q4 net income +62% to $101M; adj. EPS $1.52; pharma sales +8% FY
Q4 reported EPS $1.49 (+60% YoY); adjusted EPS $1.52 (+27% YoY).
Aptar reports Q3 net income $100M (+19%), adjusted EPS $1.49 (+6%)
Revenue $909M (+2% core sales); Pharma segment core sales +7%, Beauty -6%, Closures +4%.
Aptar reports Q2 EPS $1.34 (+8% YoY); raises dividend 10% to $0.45
Revenue $910M (+2% reported, +3% core); net income $90M (+9%).
Aptar CFO Bob Kuhn to retire Dec 31; Vanessa Kanu named successor effective Jan 1, 2025
Kuhn, CFO since 2008 and 37-year Aptar veteran, steps down Dec 31, 2024; also resigns as principal accounting officer July 31.
AptarGroup enters new credit agreement with $600M revolver and $330M term loan
New $330M unsecured term loan facility maturing July 2, 2027; revolving credit facility extended to July 2, 2029.
AptarGroup shareholders elect three directors, approve officer exculpation amendment
Elected Sarah Glickman (54.6M for), Matt Trerotola (54.3M), Ralf K. Wunderlich (55.1M) to three-year terms.
Aptar Q1 EPS $1.23 ($1.26 adj) up 50% (31% adj); revenue $915M +6%
Reported net income $83M (+52%); adjusted EBITDA $179M (+16%).
Aptar Q4 adjusted EPS $1.21 (up 27%), FY 2023 revenue $3.49B, guides Q1 2024 EPS $1.10-$1.18
Q4 reported sales $838M (+5%), net income $62M (+6%), adjusted EPS $1.21 vs $0.95 (up 27%).
Aptar Q3 adjusted EPS $1.39 (+39%), net income $84M (+55%), sales $893M (+7%)
Net income $84M (+55% YoY), reported EPS $1.26, adjusted EPS $1.39 (+39% YoY).
AptarGroup amends bylaws, sets 2024 stockholder proposal window Jan 4 – Feb 3
Bylaws amended to align with Delaware law updates and universal proxy rules.
AptarGroup appoints Sarah Glickman to board, effective Sept 5, 2023
Sarah Glickman, CFO of Criteo S.A., added to Aptar's Board of Directors on September 5, 2023.
AptarGroup Q2 net income +31% to $83M; raises dividend 8% to $0.41/share
Reported EPS $1.24, adjusted EPS $1.23 (+26% YoY); revenue $896M (+6% reported, +4% core).
Director Maritza Gomez Montiel resigns from AptarGroup board effective July 9, 2023
Maritza Gomez Montiel resigned from the Board of Directors on July 9, 2023, effective immediately.
Director Andreas Kramvis resigns from AptarGroup board effective May 6, 2023
Andreas Kramvis resigned from the Board of Directors on May 6, 2023, after many years of service.
AptarGroup shareholders approve 2018 Equity Incentive Plan amendment, adding 1.2M shares
Amendment to 2018 Equity Incentive Plan approved, increasing share reserve by 1,200,000 shares.
AptarGroup Q1 core sales +4% to $860M; adj. EPS $0.95; guides Q2 adj. EPS $1.11-$1.19
Reported sales $860M (+2% YoY); core sales +4% driven by Pharma (+7%) and Beauty (+9%); Closures -8%.
AptarGroup realigns segments into Pharma, Beauty, Closures; recasts 2022 & 2021 data
Effective Jan 1, 2023: combined all closures into Aptar Closures; renamed Beauty+Home to Aptar Beauty.
AptarGroup appoints Julie Xing as independent director effective March 1, 2023
Julie Xing, 54, appointed to AptarGroup board effective March 1, 2023; term expires at 2023 annual meeting.
AptarGroup Q4 core sales up 4%, adjusted EPS $0.92; guides Q1 $0.85-$0.93
Q4 net income $59M (+2%), reported sales $796M (-2%), core sales +4%; adj EPS $0.92 (+5%).
AptarGroup Q3 net income +15% to $54M; core sales +9%; adj EPS $0.95
Reported net income $54M (+15%), EPS $0.81 (+16%) vs $0.70.
AptarGroup appoints new director Trerotola to Corporate Governance Committee
Matthew L. Trerotola joined AptarGroup Board effective September 11, 2022.
AptarGroup appoints Matthew L. Trerotola to board effective Sept 11, 2022
Trerotola's term expires at the 2024 annual meeting of stockholders.
AptarGroup Q2 net income up 15% to $64M; core sales +10%; adjusted EPS $0.96
Reported sales $845M (+4% YoY); core sales +10%; net income $64M (+15%).
AptarGroup stockholders elect three directors, approve say-on-pay and auditor ratification
Three director nominees elected: Giovanna Kampouri Monnas, Isabel Marey-Semper, Stephan B. Tanda, each with >56M votes for and ~1M or fewer against.
AptarGroup Q1 revenue up 9% to $845M; adjusted EPS down to $0.96 from $1.05
Reported sales $845M (+9% YoY); core sales +13% with double-digit growth in all segments.
AptarGroup issues $400M 3.600% senior notes due 2032, assumes €300M in subsidiary notes
Issued $400M aggregate principal of 3.600% Senior Notes due March 15, 2032, with semi-annual interest.
AptarGroup Q4 sales up 9% to $814M; adjusted EPS $0.93 (+3%); guides Q1 adj. EPS $0.92-$1.00
Q4 reported EPS $0.85 (+8% YoY); adjusted EPS $0.93 (+3% YoY). Net income $58M.
Aptar appoints Gael Touya as President of Pharma Segment; board classes rebalanced
Effective Jan 1, 2022, Gael Touya appointed President of Pharma Segment, reporting to CEO Stephan Tanda.
AptarGroup Q3 revenue $825M (+9% YoY); adjusted EPS $0.94 vs $1.01; guides Q4 $0.88-$0.96
Reported sales $825M, +9% YoY; core sales +8%; Pharma core -2%, Beauty+Home +10%, Food+Beverage +28%.
Aptar Q2 sales up 16% to $811M, adj EPS $0.91 (+7%), core sales +10%; Q3 guidance $0.90-$0.98
Reported sales $811M (+16% YoY); core sales +10% aided by double-digit growth in Beauty+Home and Food+Beverage.
AptarGroup enters $600M unsecured multicurrency revolver; $112M term loan remains
New A&R Credit Agreement provides $600M revolving credit facility (incl. $30M swingline); replaces prior $600M facility.
Vanessa Kanu will succeed Mr. Kuhn as Executive Vice President, Chief Financial Officer of the Company, effective January 1, 2025.
Daniel Ackerman, age 51, Vice President, Corporate Controller of the Company since 2015, will become the Company’s Chief Accounting Officer, effective August 1, 2024.
and will retire as the Company’s principal accounting officer on July 31, 2024.
appointed Sarah Glickman as a director effective as of such date.
On July 9, 2023, after many years of service, Maritza Gomez Montiel notified AptarGroup, Inc. (the “Company”) of her decision to resign from the Board of Directors of the Company, effective immediately.
On May 6, 2023, after many years of service, Andreas Kramvis resigned from the Board of Directors of AptarGroup, Inc., effective immediately.
On March 1, 2023, the Board of Directors (the “Board”) of AptarGroup, Inc. (the “Company”) appointed Julie Xing as a director effective as of such date.
On September 11, 2022, the Board of Directors (the “Board”) of AptarGroup, Inc. (the “Company”) appointed Matthew L. Trerotola as a director effective as of such date.
Max materiality 0.80 · Median 0.65 · Most common event earnings